Paget’s disease of the vulva – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Paget’s disease of the vulva – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Electrochemotherapy with Bleomycin and Cisplatin for Treating Vulvar Paget’s Disease and Precancerous Lesions in Newly Diagnosed or Recurrent Patients https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-and-cisplatin-for-treating-vulvar-pagets-disease-and-precancerous-lesions-in-newly-diagnosed-or-recurrent-patients/ Wed, 29 Apr 2026 15:01:57 +0000 https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-and-cisplatin-for-treating-vulvar-pagets-disease-and-precancerous-lesions-in-newly-diagnosed-or-recurrent-patients/ This clinical trial is focused on studying the effects of a treatment called electrochemotherapy for certain conditions affecting the vulva. The conditions being studied include Paget’s disease and high-grade or initially invasive precancerous squamous lesions of the vulva. These are types of skin changes that can occur in the vulvar area, which is part of the female reproductive system. The treatment involves using two medications, Bleomycin and Cisplatin, which are administered in combination with electrical pulses to enhance their effectiveness.

The purpose of the study is to evaluate how well electrochemotherapy works in treating these vulvar conditions. Participants in the study will receive the treatment and will be monitored over a period of time to assess the response of the lesions to the treatment. The study will also look at the safety of the treatment and how long the disease remains under control after treatment. Participants will be asked to complete questionnaires about their symptoms before and after the treatment at various intervals, including one, three, six, and twelve months after the treatment.

This study aims to provide valuable information on the effectiveness and safety of electrochemotherapy for treating vulvar lesions and non-invasive Paget’s disease, potentially offering a new treatment option for these conditions. The study is expected to continue until May 2025, with recruitment having started in March 2023.

]]> Study on the Use of Methyl Aminolevulinate and PAGETEX Device for Treating Vulvar Extra-Mammary Paget’s Disease in Women https://clinicaltrials.eu/trial/study-on-the-use-of-methyl-aminolevulinate-and-pagetex-device-for-treating-vulvar-extra-mammary-pagets-disease-in-women/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-methyl-aminolevulinate-and-pagetex-device-for-treating-vulvar-extra-mammary-pagets-disease-in-women/ This clinical trial is focused on studying a condition known as Vulvar Extra-Mammary Paget’s Disease, which is a rare skin disorder affecting the vulva. The study will explore the effectiveness and safety of a treatment using a medical device called PAGETEX. This device is used in a process known as photodynamic therapy, which involves using light to activate a special cream applied to the skin. The cream used in this study is called METVIXIA, which contains an active ingredient known as methyl aminolevulinate. This treatment aims to control the disease by reducing or eliminating the affected skin areas.

The purpose of the study is to determine if the PAGETEX device can help control the disease in at least 30% of patients over a period of three months. Participants will apply the METVIXIA cream to the affected area, and the PAGETEX device will be used to deliver light therapy. The study will monitor the response to treatment, including any changes in the size or appearance of the skin lesions. The study will also assess the quality of life, pain levels, and any side effects experienced by participants during the treatment process.

Throughout the study, participants will have regular visits to evaluate their progress. These visits will include assessments by doctors and may involve taking photographs of the affected areas to track changes. The study will last for several months, with key evaluations at three and six months to determine the effectiveness of the treatment. The overall goal is to find a safe and effective way to manage Vulvar Extra-Mammary Paget’s Disease using this innovative approach.

]]>